Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 435-443

  Russell, Marie ^a   Silverman, Angela ^b   Fleg, Jerome L ^c   Lee, Elisa T ^d   Mete, Mihriye ^b   Weir, Matthew ^e   Wilson, Charlton ^a   Yeh, Fawn ^d   Howard, Barbara V ^b   Howard, Wm James ^f  

^a PHOENIX INDIAN MEDICAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

American Indians; Blood pressure; Cardiovascular disease; Carotid artery intima media thickness; Lipids

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALGORITHM; AMERICAN INDIAN; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CONSULTATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POINT OF CARE TESTING; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 77957871238     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.07.007     Document Type: Article

References (18)

1. W.B. Kannel, and D.L. McGee Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study Diabetes Care 2 1979 120 126
2. J.C. Kleinman, R.P. Donahue, M.I. Harris, F.F. Finucane, J.H. Madans, and D.B. Brock Mortality among diabetics in a national sample Am J Epidemiol 128 1988 389 401
3. W.J. Butler, L.D. Ostrander, W.J. Carman, and D.E. Lamphiear Mortality from coronary heart disease in the Tecumseh Study: Long-term effect of diabetes mellitus, glucose tolerance and other risk factors Am J Epidemiol 121 1985 541 547
4. B.V. Howard Macrovascular complications of diabetes mellitus D. LeRoith, S.I. Taylor, J.M. Olefs, Diabetes Mellitus 1996 Lippincott-Raven Philadelphia 792 797
5. R. Klein Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes Diabetes Care 18 1995 258 268
6. J.D. Brunzell, M. Davidson, and C.D. Furberg American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
7. B.V. Howard, M.J. Roman, and R.B. Devereux Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial JAMA 299 2008 1678 1689
8. M. Russell, J.L. Fleg, and W.J. Galloway Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes - the Stop Atherosclerosis in Native Diabetics Study (SANDS) Am Heart J 152 2006 867 875
9. M.R. Weir, F. Yeh, and A. Silverman Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial J Clin Hypertens (Greenwich) 11 2009 540 548
10. W.J. Howard, M. Russell, and J.L. Fleg Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering - lipoprotein changes and interactions: the SANDS study J Clin Lipidol 3 2009 322 331
11. Committee on Quality of Health Care in America Crossing the Quality Chasm: A New Health System for the 21st Century 2001 Institute of Medicine Washington, DC
12. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
13. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
14. H.N. Ginsberg, M.B. Elam, L.C. Lovato ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
15. A. Keech, R.J. Simes, and P. Barter FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
16. S.M. Grundy, J.I. Cleeman, and C.N. Merz National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
17. S.C. Smith Jr., J. Allen, S.N. Blair, and R.O. Bonow AHA/ACC; National Heart, Lung, and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
18. B.V. Howard, L.G. Best, and J.M. Galloway Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors Diabetes Care 29 2006 391 397